Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.55 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.49 |
| ▸ | MTOR | P42345 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.48 |
| ▸ | WNT1 | P04628 | 3/20 | 0.48 |
| ▸ | CDK1 | P06493 | 2/20 | 0.48 |
| ▸ | CDK2 | P24941 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 2/20 | 0.46 |
| ▸ | TAF1 | P21675 | 1/20 | 0.46 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.46 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31567826 | 0.89 | CRBN (0.60) | HRH3CRBNMEN1KMT2AALDH1A1 | |
| SCHEMBL7987541 | 0.89 | CRBN (0.60) | HRH3CRBNMEN1KMT2AALDH1A1 | |
| SCHEMBL18010687 | 0.86 | ACKR3 (0.55) | ACKR3HRH3DYRK1AWNT1CDK1 | |
| SCHEMBL13498283 | 0.86 | CRBN (0.57) | HRH3CRBNKMT2AALDH1A1 | |
| SCHEMBL4514465 | 0.85 | ACKR3 (0.54) | ACKR3HRH3PIK3CAMTORDYRK1A | |
| SCHEMBL13880681 | 0.85 | CRBN (0.54) | ACKR3CRBNMEN1KMT2ATAF1 | |
| SCHEMBL1781337 | 0.84 | ACKR3 (0.49) | ACKR3HRH3PIK3CAMTORDYRK1A | |
| SCHEMBL14094313 | 0.84 | HPGD (0.55) | HRH3CRBN | |
| SCHEMBL17996268 | 0.83 | ACKR3 (0.52) | ACKR3HRH3CDK1CDK2MEN1 | |
| SCHEMBL13880742 | 0.82 | CRBN (0.57) | CRBNMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187686-B2 | BRD4-JAK2 inhibitors | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-11643396-B2 | BRD4-kinase inhibitors as cancer therapeutics | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643396-B2 | BRD4-kinase inhibitors as cancer therapeutics | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-20210355088-A1 | BRD4-JAK2 INHIBITORS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2021-11-18 | — | — | US | disclosed |
| US-20210355088-A1 | BRD4-JAK2 INHIBITORS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2021-11-18 | — | — | US | disclosed |
| US-20200407328-A1 | BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2020-12-31 | — | — | US | disclosed |
| US-10738016-B2 | BRD4-kinase inhibitors as cancer therapeutics | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-10336734-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20190055203-A1 | POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2019-02-21 | — | — | US | disclosed |
| US-20180215738-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2018-08-02 | — | — | US | disclosed |
| CN-101448830-A | Dihydropteridine compounds as anti proliferative agents | ASTRAZENECA AB (SE) | 2009-06-03 | — | — | CN | disclosed |
| EP-2046793-A2 | FUSED PYRIMIDO COMPOUNDS | AstraZeneca AB (SE) | 2009-04-15 | — | — | EP | disclosed |
| WO-2009042711-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-02 | — | — | WO | disclosed |
| EP-2029599-A1 | DIHYDROPTERIDINE COMPOUNDS AS ANTI PROLIFERATIVE AGENTS | Astra Zeneca AB (SE) | 2009-03-04 | — | — | EP | disclosed |
| WO-2008040951-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008040951-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008003958-A2 | FUSED PYRIMIDO COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | WO | disclosed |
| US-20080009482-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
| WO-2007135374-A1 | DIHYDROPTERIDINE COMPOUNDS AS ANTI PROLIFERATIVE AGENTS | ASTRAZENECA AB (SE) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007135374-A1 | DIHYDROPTERIDINE COMPOUNDS AS ANTI PROLIFERATIVE AGENTS | ASTRAZENECA AB (SE) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200407328-A1 | BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | BRD4, BICRA, BRDT | ACKR3 1556/4885HRH3 894/4885CRBN 3103/4885 |
| US-10738016-B2 | BRD4-kinase inhibitors as cancer therapeutics | BRD4, BICRA, BRDT | ACKR3 1556/4885HRH3 894/4885CRBN 3103/4885 |
| US-20210355088-A1 | BRD4-JAK2 INHIBITORS | BRD4, BICRA, JAK2 | ACKR3 1043/4885HRH3 991/4885CRBN 1816/4885 |
| US-20080009482-A1 | NOVEL COMPOUNDS | CYP11B2, CYP11B1, CYP46A1 | ACKR3 2084/4885HRH3 2607/4885CRBN 3578/4885 |
| US-10336734-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | TNK1, TNNI3K, TNK2 | ACKR3 617/4885HRH3 1531/4885CRBN 3433/4885 |
| US-20190055203-A1 | POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | BRD4, BICRA, BRDT | ACKR3 2696/4885HRH3 1909/4885CRBN 1774/4885 |
| US-11643396-B2 | BRD4-kinase inhibitors as cancer therapeutics | BRD4, BICRA, BRDT | ACKR3 1556/4885HRH3 894/4885CRBN 3103/4885 |
| US-20180215738-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | TNK1, TNNI3K, TNK2 | ACKR3 617/4885HRH3 1531/4885CRBN 3433/4885 |
| US-12187686-B2 | BRD4-JAK2 inhibitors | BRD4, BICRA, JAK2 | ACKR3 1043/4885HRH3 991/4885CRBN 1816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.